Milnocor (Milrinone)

• Milnocor is a phosphodiesterase‑3 inhibitor indicated for conditions affecting cardiac performance.
• Acute decompensated heart failure: enhances myocardial contractility and reduces afterload to improve cardiac output.
• Cardiogenic shock: provides rapid inotropic support to restore systemic perfusion.
• Low cardiac output syndrome after cardiac surgery: stabilizes hemodynamics during postoperative recovery.

• Milrinone selectively inhibits phosphodiesterase‑3 enzymes in cardiac and vascular smooth muscle cells, leading to accumulation of intracellular cyclic AMP. Elevated cAMP enhances calcium influx in myocardial cells, producing a positive inotropic effect, while simultaneously causing vasodilation of systemic and pulmonary vessels, reducing cardiac preload and afterload.

Milnocor may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Hypotension: reduction in blood pressure, especially with rapid infusion.
• Tachyarrhythmias: premature ventricular beats or supraventricular tachycardia.
• Headache: mild to moderate intensity.
• Nausea or vomiting: gastrointestinal discomfort.
• Flushing: transient warmth and redness of skin.
• Thrombocytopenia: mild decrease in platelet count.

Serious or Rare Side Effects

• Severe hypotension: profound drop in blood pressure requiring intervention.
• Ventricular arrhythmias: life‑threatening rhythm disturbances.
• Myocardial ischemia: chest pain due to reduced coronary perfusion.
• Anaphylactic reactions: rare but potentially fatal hypersensitivity.
• Pulmonary edema: fluid accumulation in lungs.
• Liver enzyme elevation: abnormal hepatic function tests.

• Milnocor requires careful monitoring and specific safety measures before and during therapy.
• Cardiac monitoring: continuous ECG and hemodynamic assessment are essential.
• Renal impairment: dose adjustment may be needed in patients with reduced clearance.
• Severe hypotension: avoid use in patients with markedly low blood pressure.
• Concomitant vasodilators: use cautiously with other agents that lower vascular tone.
• Electrolyte balance: monitor potassium and magnesium levels to reduce arrhythmia risk.
• Store at room temperature: keep in original container, protect from moisture and light.

Milnocor can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid)

• Other phosphodiesterase‑3 inhibitors: additive inotropic and vasodilatory effects may cause severe hypotension.
• Potent vasodilators (e.g., nitroglycerin): risk of profound blood pressure drop.
• Anti‑arrhythmic agents (e.g., amiodarone): increased likelihood of ventricular arrhythmias.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may blunt the desired inotropic response.
• Diuretics: electrolyte shifts can heighten arrhythmia risk.
• ACE inhibitors or ARBs: additive blood pressure lowering effect.